My SciELO
Custom servicesServices on Demand
Journal
Article
Spanish (pdf)
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO 
Access statistics
Related links
Cited by Google 
Similars in
SciELO 
Similars in Google
Share
Permalink
Revista de la OFIL
On-line version ISSN 1699-714XPrint version ISSN 1131-9429
Abstract
ESTEBAN-CASADO, S; BARTOLOME-GARCIA, E; SANZ-MARQUEZ, S and PEREZ-ENCINAS, M. Management of angiotensin-converting enzyme inhibitors-related angioedema with icatibant. Rev. OFIL·ILAPHAR [online]. 2021, vol.31, n.3, pp.281-284. Epub May 30, 2022. ISSN 1699-714X. https://dx.doi.org/10.4321/s1699-714x2021000300006.
Objetive:
To assess the effectiveness of icatibant in the management of angiotensin-converting enzyme inhibitor-induced angioedema (AII) in a hospital without a treatment guidance.
Methods:
Observational, retrospective and descriptive study. All patients diagnossed with AII and treated with icatibant 30 mg between May 2015-December 2017 were included. The primary and secondary end-points were: time to total resolution and time to first improvement; respectively.
Results:
Five patients, median age 76 years (46-81). Four women and a man. All of them Caucasian. Median time to total resolution and to first improvement: 23 hours (IQR 20.0-25.0) and 3 hours (IQR 3.0-6.0); respectively.
Conclusion:
The early start with the anti-bradicinergic therapy may be key to the AII evolution. To achieve the maximum effectiveness and to get reduced the associated morbidity, the ICU admission and the time to discharge, the development of local protocols considering the particularities of each center is highly necessary.
Keywords : Angioedema; angiotensin; converting enzyme inhibitors; icatibant; drug-related side effects and adverse reactions.
